Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with ...
3 hours ago
0
3
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared ...
3 hours ago
0
2
Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances and titled "ATR Inhibition Activates ...
Sep 30, 2024
0
46
Angelman syndrome is a rare genetic disorder caused by mutations in the maternally-inherited UBE3A gene and characterized by poor muscle control, limited speech, epilepsy, and intellectual disabilities. Though there isn't ...
Jul 8, 2024
1
64
The National Comprehensive Cancer Network (NCCN)—a nonprofit alliance of leading cancer centers—is publishing new results for its latest survey on cancer drug shortages in the United States. This follows data published one ...
Jun 26, 2024
0
21
CCR researchers have discovered a new combination of drugs that significantly boosts the efficacy of anti-cancer treatments for colorectal cancers implanted in mice. The results, which also highlight a previously unknown ...
Jun 29, 2023
0
52
A subcutaneously implanted, catheter-pump system capable of chronic convection-enhanced delivery (CED) of topotecan is well tolerated and active for patients with recurrent glioblastoma, according to a study published in ...
Dec 1, 2022
0
34
A significant obstacle to treating brain cancer is not the cancer, but the brain itself.
Nov 11, 2022
0
163
